An official American Thoracic Society/European Respiratory Society statement: research questions in chronic obstructive pulmonary disease

…, DD Sin, JB Soriano, JK Stoller, DP Tashkin… - American journal of …, 2015 - atsjournals.org
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity,
mortality, and resource use worldwide. The goal of this Official American Thoracic Society (…

Effects of marijuana smoking on the lung

DP Tashkin - Annals of the American Thoracic Society, 2013 - atsjournals.org
Regular smoking of marijuana by itself causes visible and microscopic injury to the large
airways that is consistently associated with an increased likelihood of symptoms of chronic …

The role of long-acting bronchodilators in the management of stable COPD

DP Tashkin, CB Cooper - Chest, 2004 - Elsevier
Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting
bronchodilators are now available for use in COPD, but publications of large-scale studies …

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study

…, P O'hara, GR Owens, PD Scanlon, DP Tashkin… - Jama, 1994 - jamanetwork.com
Objective. —To determine whether a program incorporating smoking intervention and use
of an inhaled bronchodilator can slow the rate of decline in forced expiratory volume in 1 …

[HTML][HTML] A 4-year trial of tiotropium in chronic obstructive pulmonary disease

DP Tashkin, B Celli, S Senn, D Burkhart… - … England Journal of …, 2008 - Mass Medical Soc
Background Previous studies showing that tiotropium improves multiple end points in
patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term …

[HTML][HTML] Cyclophosphamide versus placebo in scleroderma lung disease

DP Tashkin, R Elashoff, PJ Clements… - … England Journal of …, 2006 - Mass Medical Soc
Background We conducted a double-blind, randomized, placebo-controlled trial to determine
the effects of oral cyclophosphamide on lung function and health-related symptoms in …

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …

DP Tashkin, MD Roth, PJ Clements… - The lancet Respiratory …, 2016 - thelancet.com
Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However, …

[HTML][HTML] Clinical significance of symptoms in smokers with preserved pulmonary function

…, R Paine III, S Rennard, DP Tashkin… - … England Journal of …, 2016 - Mass Medical Soc
Background Currently, the diagnosis of chronic obstructive pulmonary disease (COPD)
requires a ratio of forced expiratory volume in 1 second (FEV 1 ) to forced vital capacity (FVC) of …

Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

DP Tashkin, R Kanner, W Bailey, S Buist, P Anderson… - The Lancet, 2001 - thelancet.com
Background Tobacco smoking is associated with chronic obstructive pulmonary disease (COPD)
in more than 80% of cases. Our aim was to investigate the effect of sustained-release …

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised …

…, B Celli, S Kesten, T Lystig, S Mehra, DP Tashkin - The Lancet, 2009 - thelancet.com
Background The beneficial effects of pharmacotherapy for chronic obstructive pulmonary
disease (COPD) are well established. However, there are few data for treatment in the early …